157 related articles for article (PubMed ID: 36672182)
61. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
62. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
63. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
64. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
[TBL] [Abstract][Full Text] [Related]
65. [Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines].
Deng HB; Liu MJ; Jiang YY; Yuan T; Zhang R; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):747-751. PubMed ID: 34753229
[No Abstract] [Full Text] [Related]
66. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
[TBL] [Abstract][Full Text] [Related]
67. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
68. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
69. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
[TBL] [Abstract][Full Text] [Related]
70. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
71. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
72. [Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration].
Chen ML; Peng N; Liu XY; Zhang T; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):217-223. PubMed ID: 33910307
[No Abstract] [Full Text] [Related]
73. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
74. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
75. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
76. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
77. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
78. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
79. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
[TBL] [Abstract][Full Text] [Related]
80. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
